Diagnostic value of urinary luteinizing hormone levels in the monitoring of precocious puberty treatment


Creative Commons License

Yuce O., BİDECİ A. , ÇELİK N., Camurdan O., CİNAZ P.

ARCHIVES OF ENDOCRINOLOGY METABOLISM, vol.64, no.2, pp.121-127, 2020 (Journal Indexed in SCI) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 64 Issue: 2
  • Publication Date: 2020
  • Doi Number: 10.20945/2359-3997000000212
  • Title of Journal : ARCHIVES OF ENDOCRINOLOGY METABOLISM
  • Page Numbers: pp.121-127
  • Keywords: Monitoring, precocious puberty, urinary gonadotropin, GnRH analogues, GONADOTROPIN MEASUREMENTS, DEPOT LEUPROLIDE, LH, CHILDREN, EXCRETION, HEIGHT, SERUM, GIRLS, AXIS, AGE

Abstract

Objective: To determine whether first-voided urinary LH (FV-ULH) - level measurement can adequately assess pubertal suppression as much as standard tests can. Subjects and methods: The study group included patients with central precocious puberty and rapidly progressing early puberty who received up to 3 - 4 doses of GnRHa therapy monthly and did not have adequate hormonal suppression after GnRH stimulation (90-minute LH level > 4 IU/L). Design: All of the participants underwent an LHRH test just after admission to the study. According to the stimulated peak LH levels, the patients were divided into 2 groups and followed until the end of the first year of treatment.The concordance between FV-ULH and stimulated LH levels was assessed. Results: The FV-ULH levels in patients with inadequate hormonal suppression were significantly high compared to patients with adequate hormonal suppression. FV-ULH levels were very strongly correlated with stimulated LH levels (r = 0.91). Its correlation with basal LH levels was significant (r = 0.65). However, this positive correlation was modestly weakened after the first year of treatment.The cutoff value for FV-ULH of 1.01 mlU/mL had the highest sensitivity (92.3%) and specificity (100%). Conclusion: FV-ULH levels, using more reliable and sensitive assay methods, can be used to monitor the adequacy of GnRHa therapy.